Effects of raloxifene use on cardiovascular disease risk determinants in postmenopausal women

Banu Ciftci; Haldun Guner

doi:10.18203/2320-1770.ijrcog20242467

Authors

Banu Ciftci Department of Obstetrics and Gynecology, Private Clinic, Istanbul, Turkey
Haldun Guner Department of Obstetrics and Gynecology, Private Clinic, Istanbul, Turkey

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20242467

Keywords:

Raloxifene, Postmenopausal, Menopausal hormone therapy, Cardiovascular disease

Abstract

Background: Raloxifene is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors with high affinity, acting as an estrogen agonist or antagonist in a tissue-specific manner. This study aimed to evaluate the effect of raloxifene on various cardiovascular risk determinants in postmenopausal women and to compare these effects with those in a control group.

Methods: The study was conducted as a prospective, open, matched case-control study at Gazi University Hospital. A total of 100 postmenopausal women were included. Fifty postmenopausal women with osteoporosis received 60 mg of raloxifene daily. The other fifty healthy postmenopausal women in the control group received no treatment. After one year, changes in cardiovascular risk markers compared to baseline values were evaluated in both the treatment and control groups. The plasma determinants evaluated included total cholesterol, LDL, HDL, triglycerides, lipoprotein (a), Apo A, Apo B, homocysteine, hs-CRP, and fibrinogen. Carotid intima-media thickness, an important radiologic indicator of cardiovascular risk, was also measured and compared between the groups.

Results: After the study, raloxifene was found to decrease levels of total cholesterol, LDL, homocysteine, and fibrinogen, but it did not affect HDL, triglyceride, Apo B, lipoprotein (a), and hs-CRP levels. There were no differences between the baseline values of the groups or the values of the control group after the study period. In the control group, there was a significant increase in carotid intima-media thickness compared to baseline values, while no such difference was observed in the raloxifene group.

Conclusions: Raloxifene caused favorable changes in many biochemical and radiologic cardiovascular risk determinants compared to the control group. Further clinical studies are needed to determine whether these effects are associated with cardiovascular protection.

Metrics

Metrics Loading ...

References

Kinci MF, Sezgin B, Arslaner MO, Akin Gökbel D, Gökbel İ, Sivaslioğlu AA. Anatomical and symptomatic outcomes in patients with Le Fort colpocleisis with or without hysterectomy. BMC Women's Health. 2022;22(1):286.

Brzozowska M, Lewiński A. Changes of androgens levels in menopausal women. Menopause Review/Przegląd Menopauz. 2020;19(4):151-154.

Bugra C, Burcin SO, Burcu K, Bora C, Ferdi KM, Eser C, et al. Is presence time of dermoid cysts a risk factor for malignancy potential in advanced age? Int J Gerontol. 2019;13:335-8.

Rosano G, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric. 2007;10(sup1):19-24.

Muka T, Oliver-Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PloS one. 2016;11(6):e0157417.

Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Annu. Rev. Public Health. 2005;26(1):115-140.

Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Medi. 2020;382(5):446-455.

Lobo RA, Pickar JH, Stevenson JC, Mack WJ, Hodis HN. Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis. 2016;254:282-90.

Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstetr Gynecol. 1999;180(3):S312-6.

Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Molecul Biol. 2014;142:142-154.

Bolognese MA. SERMs and SERMs with estrogen for postmenopausal osteoporosis. Revi Endocri Metabol Disord. 2010;11(4):253-9.

Lello S, Capozzi A, Scambia G. Is there still a role for SERMs in menopause management?. Gynecol Endocrinol. 2020;36(7):567-8.

Howell A. Tamoxifen versus the newer SERMs: what is the evidence? Ann Oncol. 2000;11:255-66.

Hansdóttir H. Raloxifene for older women: a review of the literature. Clin intervent Agi. 2008;3(1):45-50.

World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992], 1994. Available at: https://iris.who.int/handle/10665/39142. Accessed on 01 March 2024.

Bodur S, Dundar O, Kanat-Pektas M, Kinci MF, Tutuncu L. The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: a randomızed controlled study. Taiwan J Obstetr Gynecol. 2018;57(3):411-6.

Santhiyakumari N, Madheswaran M. Extraction of intima-media layer of arteria-carotis and evaluation of its thickness using active contour approach. In2007 International Conference on Intelligent and Advanced Systems 2007 Nov 25. IEEE. 2007;582-586.

Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Jama. 2002;287(7):847-57.

Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Jama. 1998;279(18):1445-51.

Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metabol. 2000;85(1):214-8.

Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337(23):1641-7.

Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis. 1996;126(1):65-75.

Smolders RG, Vogelvang TE, Mijatovic V, van Baal WM, Neele SJ, Netelenbos JC, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein (a) and homocysteine. Maturitas. 2002;41(2):105-114.

Mijatovic V, van der Mooren MJ, Kenemans P, de Valk-de Roo GW, Netelenbos C. Raloxifene lowers serum lipoprotein (A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause. 1999;6(2):134-7.

Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins AI and B as predictors of angiographically defined coronary artery disease. Arch Int Medi. 1990;150(8):1629-33.

Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscl Thrombos Vasc Biol. 1999;19(4):893-9.

Crouse J, Thompson C. An evaluation of methods for imaging and quantifying coronary and carotid lumen stenosis and atherosclerosis. Circulation. 1993;87(3 Suppl):II17-33.

Poli A, Tremoli E, Colombo A, Sirtori M, Pignoli P, Paoletti R. Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients A new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects. Atheroscl. 1988;70(3):253-261.

de Kleijn MJ, Bots ML, Bak AA, Westendorp IC, Planellas J, Bennink HJ, et al. Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. Maturitas. 1999;32(3):195-204.

Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Ame J Epidemiol. 1995;142(10):1011-9.

Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Progr Cardiovas Dis. 1995;38(3):199-210.

Kauffman RF, Bensch WR, Bean JS. Effects of estrogen and raloxifene, a selective estrogen receptor modulator, in animal models of vascular injury. Estrogen and the vessel wall: CRC Press; 1998:207-217.

Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril. 1998;70(6):1085-9.